# ZSHK Lab

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zshk-lab

- Industry: Biotechnology
- Headquarters: Hong Kong, Hong Kong SAR - China
- Website: www.zshklabs.com
- Total disclosed funding: $15M
- Latest round: Series A (Jul 26, 2021)
- Investors on record: 2

## About

Based in Hong Kong, and founded in 2017, ZSHK Lab is a biopharmaceutical pre-clinical research and development service company that offers pharmacodynamic screening, pharmacodynamic evaluation, metabolism, safety evaluation, and clinical biological sample analysis solutions. In July 2021, ZSHK Lab raised CNY 100 million in series A funding led by investor Qiming Venture Partners, with participation from another investor, Ascendum Capital Partners. As of 2022, the company is led by its CEO, Li Ming.

The company offers pharmaceutical research and development solutions that include pharmacology and pharmacodynamics, safety pharmacology, drug metabolism, drug safety evaluation, clinical pathology and pathology, bioanalysis, rodent, and non-rodent surgery, and many more. The company also provides support platforms like IT and computerized systems, instrument management systems, archive management systems, file management systems, and document management systems.

The company plans to use the July 2021 funding for laboratory construction, the introduction of high-end talents, and business expansion.

## Funding rounds

- Series A, Jul 26, 2021, $15M — Qiming Venture Partners, Ascendum Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- Ascendum Capital (https://capitalatlas.ai/funds/ascendum-capital) — Series A